Simply Wall St.
High Growth Tech Stocks To Watch In The US January 2026
📈
AI Sentiment
Highly Positive
9/10
- Home
- VRDN
as of 01-22-2026 3:45pm EST
$32.11
$0.19
-0.57%
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 2.7B | IPO Year: | N/A |
| Target Price: | $41.17 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.90 - $34.29 | Next Earning Date: | 02-26-2026 |
| Revenue: | $70,789,000 | Revenue Growth: | 23340.07% |
| Revenue Growth (this year): | 26257.62% | Revenue Growth (next year): | 4.54% |
AI-Powered VRDN Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 0.00%
0.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Viridian Therapeutics Inc. (VRDN)
Tousignant Jennifer
Sell
Chief Legal Officer
VRDN Dec 31, 2025
Avg Cost/Share
$31.16
Shares
2,272
Total Value
$70,795.52
Owned After
0
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Tousignant Jennifer | VRDN | Chief Legal Officer | Dec 31, 2025 | Sell | $31.16 | 2,272 | $70,795.52 | 0 |
Latest Viridian Therapeutics Inc. News
VRDN Breaking Stock News: Dive into VRDN Ticker-Specific Updates for Smart Investing
Simply Wall St.
US High Growth Tech Stocks To Watch In January 2026
📈
AI Sentiment
Highly Positive
9/10
Compare VRDN vs Leading Stocks
See how VRDN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VRDN Viridian Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.